Dr. Wroblewski is currently a Research Fellow in the Pharmaceutical Biotechnology Center at Indiana Biosciences Research Institute. He obtained his B.S. from Syracuse University and Ph.D. from the University at Buffalo and performed post-doctoral research at the University of California at Davis. Dr. Wroblewski worked for 5 years at the Bayer Corporation and over 25 years at Eli Lilly and Company before retiring and joining the IBRI.
Responsibilities of recently held positions at Eli Lilly and Company include the direction of a team of 30 scientists (12 Ph.D. level) charged with supporting the preclinical development of Lilly’s biotechnology portfolio (monoclonal antibodies, multi-functional antibodies, fusion proteins and peptides). The group was built in a multi-disciplinary fashion to include scientists with backgrounds in immunology, analytical chemistry, biochemistry, protein engineering and pharmacokinetics; engaging closely protein engineering to allow early evaluation and optimization of structure-function relationships in the discovery phase. The group integrated with therapeutic area biologists in oncology, immuno-oncology, auto-immune and metabolic disease/cardiovascular to develop pre-clinical models and biomarkers to support PK/PD modeling and translation of safe and efficacious doses for initial human studies. He and his team contributed directly to the successful development of a number of marketed biologic therapeutics including humalog, humatrope, ixekizumab, dulaglutide, erbitux/necitumumab and olaratumab.